PF299804

• CAT Number: I000449
• CAS Number: 1110813-31-4
• Molecular Formula: C₂₄H₂₅ClFN₅O₂
• Molecular Weight: 469.94
• Purity: 98%
• Synonyms: (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
• Target: Protein Tyrosine Kinase/RTK
• Target Protein: P00533
• Solubility: DMSO: 19 mg/mL，H2O：< 1 mg/mL
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: EGFR:6 nM (IC50)
• InChI: InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
• InChIKey: LVXJQMNHJWSHET-AATRIKPKSA-N
• SMILES: COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4

PF-299804 (Cat No.:I000449) is a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. By targeting and inhibiting EGFR, Dacomitinib blocks the signaling pathways involved in cancer cell growth, proliferation, and survival. Its irreversible binding to the receptor provides prolonged inhibition compared to earlier-generation TKIs, improving its efficacy, especially in tumors resistant to first-line EGFR inhibitors. Dacomitinib offers an effective treatment option for patients with advanced NSCLC, particularly those with EGFR-driven mutations.